Ingenol Mebutate (Picato) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

Trial Profile

Ingenol Mebutate (Picato) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Ingenol mebutate (Primary) ; Methyl aminolevulinate (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
    • 06 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top